Documents
identified with this icon are in Portable Document Format (PDF) and require the
The effect of the first-generation HCV-protease inhibitors boceprevir and
telaprevir and the relation to baseline NS3 resistance mutations in genotype 1:
experience from a small Swedish cohort.
Boceprevir or telaprevir in hepatitis C virus chronic infection:
The Italian real life experience.
Optimisation of triple therapy for patients with chronic hepatitis C: a
systematic review.
Kjellin M, Wesslén T, Löfblad E,et
al
Ups J Med Sci.
2018 Mar 14:1-7
Abstract
Cuypers L, Libin P, Schrooten Y, et al
Infect Genet Evol.
2017 May 9.
Abstract
Mangia
A, Foster GR, Berg CP, et al
Ann Gastroenterol. 2017;30(3):327-343.
Abstract
Borba
HH, Wiens A, Steimbach LM,
Ther Clin Risk Manag. 2017 Jan 10;
Abstract
i LE,World J
Hepatol. 2016 Aug 8;
Abstract
Eur
J Clin Invest.
2016 Aug;46(8):737-48.
Abstract
Xavier F, Didier S, Mutimer D,
et al
Ann Hepatol. 2016
Jul-Aug;15(4):512-23.
Abstract
Telaprevir-containing regimen for treatment of hepatitis C virus infection
in patients with hepatocellular carcinoma awaiting liver transplantation: a
case series
Retreatment of Chronic Hepatitis C Infection with Telaprevir : Turkey
Experience.
Torres HA, Kaseb A, Mahale P,
et al
J Hepatocell Carcinoma. 2014 Jul
16;1:109-14.
Abstract
Kanda T, Nakamoto S, Sasaki R,
et
al
Int J Med Sci.
2016 Apr 10;13(4):310-5.
Paper
Acta Gastroenterol Belg. 2016
Jan-Mar;79(1):18-22.
Abstract
Hoffmann
L, Faffe DS, Lima JF, et al
BBA Clin.
2015 Jan 30;3:146-151.
Abstract
Impact of telaprevir in HCV patients with cirrhosis and RVR:
real-life data from Boceprevir or Telaprevir based "triple therapy"
experience in southern Italy.
FULL-TEXT ARTICLE
FULL-TEXT ARTICLE
A case report: antiviral triple therapy with telaprevir in a haemodialysed
HCV patient in Turkey.
Morisco F, Masarone M, Rosato V,
et al
Rev Recent Clin Trials. 2015
Dec 17
Abstract
About F, Oudot-Mellakh T, Niay J, et al
PLoS One. 2015 Dec
15;10(12):e0145105.
Paper
Importance of virological response in the early stage of
telaprevir-based triple therapy for hepatitis
C.
World J
Hepatol. 2015
Nov 18;7(26):2688-2695.
Paper
Montes ML, Nelson M, Girard PM,
et al
J Antimicrob Chemother. 2015 Oct 19.
Abstract
Kawaguchi
Y, Iwane S, Kumagai T,
et al
Intern Med.
2015;54(20):2551-60.
Abstract
Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety
and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis.
PLoS One. 2015 Sep
23;10(9):e0138503.
Paper
Dore GJ, Conway B, Luo Y, et al
J Hepatol. 2015 Aug 27.
Abstract
Garbuglia
AR, Lionetti R, Lapa D,
et
al
J Clin Virol.
2015 Aug;69:68-73.
Abstract
Calisti G, Tavares A, Macartney MJ,
et al
Springerplus.
2015 Jul 16;4:357.
Abstract
Acta Clin
Belg. 2015 Jul 6
Abstract
Retreatment of Chronic Hepatitis C Infection with Telaprevir:
Preliminary Results in Turkey.
FULL-TEXT
ARTICLE
Aygen B, Yıldız O,
Akhan S, et al
Balkan Med J.
2015 Jul;32(3):266-72.
Abstract
Management of
telaprevir-based triple therapy for hepatitis C virus recurrence post liver
transplant.
World J Hepatol.
2015 May 28;7(9):1287-96.
Paper
High efficacy and safety of triple therapy in HCV genotype 1 and moderate
fibrosis: a multicenter study of clinical practice in Spain.
Pharmacokinetic and pharmacodynamic evaluation of telaprevir for
the treatment of hepatitis C.
Telaprevir may induce adverse cutaneous reactions by a T cell
immune-mediated mechanism.
Crespo J, Diago M, Cabezas J, et al
Ann Hepatol. 2015
;14(4):477-486.
Abstract
Expert Opin Drug Metab Toxicol.
2015 May 25:1-9
Abstract
Matsui K, Kamijo-Ikemori A, Sugaya T, et al
Nephrology (Carlton).
2015 May 22.
Abstract
Ann
Hepatol. 2015 May-Jun 2015;14(3):420-424.
Abstract
Intracellular and Plasma Trough Concentration and Pharmacogenetics of
Telaprevir.
Cusato J, Allegra S, De Nicolò A,
et al
J Pharm Pharm Sci.
2015 Apr-Jun;18(2):171-176.
Abstract
Le
TK, Kalsekar A, Macaulay D, et al
J Manag Care Spec Pharm. 2015
Apr;21(4):308-318.
Abstract
Telaprevir and ribavirin interaction: higher ribavirin levels are
not only due to renal dysfunction during triple therapy.
Gutierrez-Valencia A,
Ruiz-Valderas R, Ben-Marzouk-Hidalgo OJ, et al
Antimicrob Agents Chemother. 2015 Mar 23.
Abstract
Successful treatment with telaprevir of post-transplant fibrosing cholestatic
hepatitis C in an HIV co-infected patient.
Marciano S, Galdame OA, Barcan LA, Gadano AC.
Acta Gastroenterol Latinoam.
2015 Mar;45(1):76-9.
Abstract
FULL-TEXT ARTICLE
First-generation protease
inhibitor-triple therapy: SVR 24, safety, and predictors of response in a large
single center cohort.
Werner CR, Franz C, Egetemeyr DP, et al
Virol J. 2015 Mar
3;12(1):37.
Paper
Verna
EC, Saxena V, Burton JR Jr, et al
Transplantation. 2015
Feb 24.
Abstract
Sarrazin C, Dierynck I, Cloherty G,
et al
J Clin Microbiol. 2015
Feb 4
Abstract
Sterling RK, Kuo A, Rustgi VK,
et al
Aliment Pharmacol Ther.
2015 Jan 28
Abstract
Early virological assessment during telaprevir- or
boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a
previous interferon based regimen - The ANRS CO20-CUPIC study.
Bailly F, Virlogeux V, Dufour C, et al
Clin Res Hepatol Gastroenterol.
2015 Jan 27. pii: S2210-7401(15)00002-9
Abstract
Verweij-van Wissen CP, de Graaff-Teulen MJ, et
al
Ther Drug Monit. 2015 Jan 26.
Abstract
Manzano-Robleda
MD, Ornelas-Arroyo V, et al
Ann Hepatol. 2015 Jan-Feb
2015;14(1):46-57.Z
Abstract
Tamori
A, Kioka K, Sakaguchi H, et al
Ann Hepatol. 2015 Jan-Feb
2015;14(1):28-35.
Abstract
Successful treatment with telaprevir-based regimens for chronic
hepatitis C results in significant improvements to serum markers of liver
fibrosis.
Haseltine EL, Penney
MS, George S, Kieffer TL.
J Viral Hepat. 2015 Jan 13.
Abstract
SLC29A1 polymorphism and prediction of anaemia severity in
patients with chronic hepatitis C receiving triple therapy with telaprevir.
Milazzo L, Peri AM,
Mazzali C, et al
J Antimicrob Chemother. 2015 Jan 11. pii:
dku519
Abstract
Multicenter Prospective Study to Optimize the Efficacy of Triple Therapy with
Telaprevir in Patients with Genotype 1b HCV Infection According to
an Algorithm Based on the Drug Adherence, IL28B Gene Allele and Viral Response:
the AG & RGT Trial.
Sugawara K, Koushima Y,
Inao M, et al
Hepatol Res. 2015 Jan 9
Abstract
Telaprevir enhances ribavirin-induced anaemia through renal function impairment.
Cotte L, Barrail-Tran A, Vincent C, et al
Antivir Ther.
2014 Jan 6
Abstract
Telaprevir-based triple therapy for hepatitis C null responders among living
donor liver transplant recipients.
Kaneko J, Sugawara Y, Yamaguchi T, Harada N, et al
Biosci Trends.
2014;8(6):339-45.
Abstract
Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of
virological failure during telaprevir-based triple therapy in clinical
practice.
Cento V, Tontodonati M, Di Maio VC, et al
Dig Liver Dis. 2014 Dec
27
Abstract
Virologic response and haematologic toxicity of boceprevir- and
telaprevir-containing regimens in actual clinical settings.
Butt AA, Yan P, Shaikh OS, et al
J Viral Hepat. 2014
Dec 18.
Abstract
Takita
M, Hagiwara S, Kudo M, et al
Oncology. 2014;87 Suppl
1:110-117.
Abstract
Nakagawa A, Atsukawa M,
Tsubota A, et al
Eur J Gastroenterol Hepatol.
2014 Dec;26(12):1329-1334.
Paper
Drug-drug interactions of telaprevir and boceprevir in
HCV-monoinfected and HIV/HCV-coinfected patients can modify the adherence.
Gonzalez-Colominas
E, Broquetas T, et al
Liver Int. 2014 Nov 10.
Abstract
Role of telaprevir plasma levels for predicting response to
antiviral therapy in patients with hepatitis C virus genotype 1 infection.
Farnik H, Ferreirós N,
Labocha S, et al
Scand J Gastroenterol. 2014 Nov 11:1-7.
Abstract
Nakagawa
A, Atsukawa M, Tsubota A, et al
Eur J Gastroenterol Hepatol.
2014 Dec;26(12):1329-1334.
Abstract
Adjusting the starting dose of telaprevir according to renal
function decreases adverse effects and affects the sustained virological
response rate.
Drug-drug Interaction with Telaprevir or Boceprevir in Liver
Transplant Patients: About Four Cases
Serum granulysin levels as a predictor of serious telaprevir-induced
dermatological reactions
Morihara D, Watanabe H,
Takata K, et al
Eur J Gastroenterol Hepatol.
2014 Nov 3
Abstract
Therapie. 2014
Oct 17
Abstract
Hepatol Res. 2014 Sep
11.
Abstract
Safety Profile of Boceprevir and Telaprevir in Chronic Hepatitis C: Real-World
Experience From HCV-TARGET.
FULL-TEXT ARTICLE
Effect of telaprevir on the metabolism and hepatic uptake of
tacrolimus (FK506).
Effects of boceprevir and telaprevir on the pharmacokinetics of
dolutegravir.
FULL-TEXT ARTICLE α-Fetoprotein is a surrogate marker for predicting treatment failure in telaprevir-based triple combination therapy for genotype 1b chronic hepatitis C
Gordon SC, Muir AJ, Lim JK, et al
J Hepatol.
2014 Sep 9. pii: S0168-8278(14)00647-3
Abstract
Malone DF, Falconer K, Weiland O, Sandberg JK.
PLoS One. 2014 Aug
28;9(8):e105665
Paper
Wire MB, Fang L, Hussaini A, et al.
Antimicrob Agents Chemother.
2014 Aug 25.
Abstract
Modeling Viral Evolutionary Dynamics after Telaprevir-Based Treatment.
PLoS Comput Biol.
2014 Aug
7
Paper
Costs of Telaprevir-based Triple Therapy for Hepatitis C: $189,000 per
Sustained Virologic Response.
Bichoupan
K, Martel-Laferriere V, Sachs D, et al
Hepatology.
2014 Jul 28.
Abstract
Biopharm Drug Dispos.
2014 Jul 24
Abstract
Aherfi
S, Solas C, Motte A, et al
J Med
Virol. 2014 Jul 23.
Abstract
Laouénan
C, Marcellin P, Lapalus M,
et al
Antimicrob Agents Chemother.
2014 Jun 30.
Abstract
Colombo M, Strasser SI, Moreno C, et al
J Hepatol. 2014 Jun 16.
Abstract
Roos K, Gotthardt D, Giese T, et al
Liver Transpl.
2014 Jun 3.
Abstract
Abe H, Tsubota A, Shimada N, Atsukawa M, et
al
Hepatol Res. 2014 May 22.
Abstract
Br J Clin Pharmacol.
2014 May 16
Abstract
Ogawa
E, Furusyo N, Nakamuta M, et al
J Gastroenterol Hepatol. 2014 Apr 14.
Abstract
Kwo PY, Ghabril M, Lacerda MA, et al
C
lin Transplant. 2014 Apr 8.
Abstract
Hezode
C, Fontaine H, Dorival C, et al
Gastroenterology.
2014 Apr 3.
Abstract
Saxena V, Manos MM, Yee HS, et al
Aliment Pharmacol Ther.
2014 Mar 24
Abstract
Boglione L, De
Nicolò A, Cusato J, et al
J Viral Hepat. 2014
Apr;21(4):260-3.
Abstract
Cost-effectiveness of Telaprevir Combination Therapy for Chronic Hepatitis C
PLoS One.
2014 Mar 6;9(3):e90295.
Paper
Macartney MJ, Irish D, Bridge SH, Garcia-Diaz A, et al
Antiviral Res.
2014 Mar 1.
Abstract
Japanese patients with the IL28B minor genotype.
J Med Virol. 2014 Mar;86(3):461-72.
Abstract
Virological response rates for telaprevir-based hepatitis C triple
therapy in patients with and without HIV coinfection.
Martel-Laferrière
V, Brinkley S, Bichoupan K, et al
HIV
Med.
2014
Feb;15(2):108-15.
Abstract
Telaprevir-Induced DRESS.
Kesar V, Kesar V, Khaitova V,
et al
J Drugs Dermatol. 2014 Feb
1;13(2):199-200.
Abstract
Risk factors predictive of anemia development during telaprevir plus
peginterferon/ribavirin therapy in treatment-experienced patients.
Zeuzem
S, Demasi R, Baldini A, et
al
J
Hepatol. 2014 Jan 28
Abstract
Influence of low-density lipoprotein cholesterol on virological response to telaprevir-based triple therapy for chronic HCV genotype 1b infection.
Ogawa E, Furusyo N, Kajiwara E, et al
Antiviral Res. 2014 Jan 22.
Abstract
